APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Ian D Schnadig1, Richy Agajanian2, Christopher Dakhil3, Nashat Gabrail4, Jeffrey Vacirca5, Charles Taylor6, Sharon Wilks7, Eduardo Braun8, Michael C Mosier9, Robert B Geller10, Lee Schwartzberg11, Nicholas Vogelzang12 1Compass Oncology, US Oncology Research, Tualatin, OR, 2The Oncology Inst...

Full description

Bibliographic Details
Main Authors:	Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-05-01
Series:	Cancer Management and Research
Subjects:	APF530 extended release granisetron chemotherapy induced nausea and vomiting (CINV) highly emetogenic chemotherapy (HEC) anthracycline cyclophosphamide
Online Access:	https://www.dovepress.com/apf530-versus-ondansetron-each-in-a-guideline-recommended-three-drug-r-peer-reviewed-article-CMAR

Similar Items

Clinician preference and comparison of the efficacy of ondansetron, granisetron, and palonosetron in preventing chemotherapy-induced nausea and vomiting among children receiving moderate or highly emetogenic chemotherapy
by: Rohan Bansal, et al.
Published: (2023-09-01)

Chemotherapy induced nausea and vomiting may cause anxiety and depression in the family caregivers of patients with cancer
by: Xiaozhen Luo, et al.
Published: (2023-09-01)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
by: Laurent Zelek, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy
by: Yu Kondo, et al.
Published: (2022-06-01)

Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
by: Akihiro Uchiike, et al.
Published: (2023-08-01)

Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
by: António Araújo, et al.
Published: (2023-01-01)

A deep learning‐based interpretable decision tool for predicting high risk of chemotherapy‐induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy
by: Jingyue Zhang, et al.
Published: (2023-09-01)

Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
by: Soumya Simhadri, et al.

A Randomized Comparison of Granisetron Plus Dexamethason with Granisetron alone for the Control of Acute Chemotherapy-Induced Emesis and Nausea
by: Shahrbanou Keyhanian, et al.
Published: (2009-04-01)

A Randomized Comparison of Granisetron Plus Dexamethason with Granisetron alone for the Control of Acute Chemotherapy-Induced Emesis and Nausea
by: Shahrbanou Keyhanian, et al.
Published: (2009-06-01)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
by: Ai Gao, et al.
Published: (2023-07-01)

Mechanisms of Chemotherapy-Induced Neurotoxicity
by: Halina Was, et al.
Published: (2022-03-01)

A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
by: Yilan Jin, et al.
Published: (2023-11-01)

Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan
by: Munenobu Kashiwa, et al.
Published: (2019-07-01)

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
by: Aziz Eghbali, et al.
Published: (2023-07-01)

Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial
by: Der Sheng Sun, et al.
Published: (2023-05-01)

Symptom and Anxiety Assessment in Gynecologic Cancer Patients Receiving Chemotherapy
by: Pongsaton Viriyasiri, et al.
Published: (2020-06-01)

Therapeutic study of the nausea and vomiting caused by chemotherapy medications by olanzapine to triple antiemetic therapy in Iraqi cancer patients
by: Ghufran salah ahmed, et al.
Published: (2023-05-01)

Metronomic chemotherapy regimens in oncology
by: M. Yu. Fedyanin, et al.
Published: (2016-04-01)

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
by: Luigi Celio, et al.
Published: (2022-08-01)

The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy
by: Aziz Eghbali, et al.
Published: (2023-01-01)

Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
by: So Rae Lee, et al.
Published: (2020-09-01)

Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes
by: Joaquim Soares do Brito, et al.
Published: (2023-06-01)

COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER
by: A. S. POPOVA, et al.
Published: (2017-06-01)

Comparative Study of an Ondansetron and a Ramosetron an Aprepitant in the Control of Nausea and Vomiting in Gynecologinc Cancer Patient with Chemotherapy
by: HANGGOO Yun, et al.
Published: (2013-12-01)

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
by: Lee Schwartzberg, et al.
Published: (2019-05-01)

Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial
by: Sukpiriyagul A, et al.
Published: (2023-08-01)

Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class—A Meta-Analysis
by: Anthony B. Daniels, et al.
Published: (2021-05-01)

A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes
by: Ji Hyun Kim, et al.
Published: (2021-09-01)

Path Planning and Trajectory Optimization Based on Improved APF and Multi-Target
by: Jie Yang, et al.
Published: (2023-01-01)

Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens
by: Ahmad Ahmadzadeh, et al.
Published: (2014-06-01)

Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug
by: Xiao-Ling Zhang, et al.
Published: (2022-10-01)

Comparative Study on the Efficacy of Two Perioperative Chemotherapy Regimens for Lumbar Brucellosis
by: Wang J, et al.
Published: (2023-11-01)

CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING
by: I. A. Koroleva, et al.
Published: (2017-11-01)

APF Applied on PV Conversion Chain Network Using FLC
by: Bourourou Fares, et al.
Published: (2023-04-01)

SHORT-TERM CHEMOTHERAPY REGIMEN OF MULTIDRUG-RESISTANT TUBERCULOSIS IN THE KYRGYZ REPUBLIC
by: E.V. ZHDANOVA, et al.
Published: (2018-08-01)

Optimized APF-ACO Algorithm for Ship Collision Avoidance and Path Planning
by: Mingze Li, et al.
Published: (2023-06-01)

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status
by: M. Yu. Fedyanin, et al.
Published: (2018-05-01)

Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
by: Takashi Yokokawa, et al.
Published: (2023-09-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
by: N. V. Dobrova, et al.
Published: (2015-02-01)